ViiV’s Bid To Switch HIV Patients To Cabenuva Boosted By Biktarvy Head-To-Head
90% Of Participants Happy With Switch
A new head-to-head proves Cabenuva is a match for Gilead’s Biktarvy, which should boost uptake of the long-acting HIV treatment.
You may also be interested in...
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.
The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.